Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALPG | P10696 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909428 | 0.86 | MAPK1 (0.55) | MAPK1TSHRMAPTPKMALDH1A1 | |
| SCHEMBL1982270 | 0.85 | L3MBTL1 (0.61) | MAPK1TSHRMAPTPKMALDH1A1 | |
| SCHEMBL28244904 | 0.81 | TSHR (0.58) | MAPK1TSHRMAPTPKMALDH1A1 | |
| SCHEMBL437440 | 0.81 | TSHR (0.58) | MAPK1TSHRMAPTPKMALDH1A1 | |
| SCHEMBL27958762 | 0.81 | TSHR (0.58) | MAPK1TSHRMAPTPKMALDH1A1 | |
| SCHEMBL14092704 | 0.81 | VCAM1 (0.53) | MAPK1MAPTKMT2AALDH1A1CYP1A2 | |
| SCHEMBL2976885 | 0.81 | MAPT (0.58) | MAPK1TSHRMAPTPKMALDH1A1 | |
| SCHEMBL16752918 | 0.81 | MAPK1 (0.53) | MAPK1TSHRMAPTPKMALDH1A1 | |
| SCHEMBL2016758 | 0.81 | MAPT (0.63) | MAPK1TSHRMAPTPKMALDH1A1 | |
| SCHEMBL15224321 | 0.80 | MAPT (0.44) | MAPK1TSHRMAPTPKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104130143-B | Method for preparing 3-methylamino-4-nitrophenoxyethanol | 江苏鼎龙科技有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-104130143-A | Method for preparing 3-methylamino-4-nitrophenoxyethanol | ZHEJIANG DRAGON CHEMICAL CO LTD | 2014-11-05 | — | — | CN | claimed |
| CN-101068770-B | Process for producing 6-substituted-1-methyl-1-H-benzimidazole derivative and synthetic intermediate therefor | SANKYO CO | 2012-01-04 | — | — | CN | claimed |
| US-7816552-B2 | Intermediate of 6-substituted 1-methyl-1-H-benzimidazole derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | claimed |
| US-20090023929-A1 | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same | SANKYO COMPANY, LIMITED (JP) | 2009-01-22 | — | — | US | claimed |
| CN-101068770-A | Process for producing 6-substituted-1-methyl-1-H-benzimidazole derivative and synthetic intermediate therefor | SANKYO CO (JP) | 2007-11-07 | — | — | CN | claimed |
| EP-1798216-A1 | INTERMEDIATE OF 6-SUBSTITUTED-1-METHYL-1-H-BENZIMIDAZOLE DERIVATIVE AND METHOD FOR PRODUCING SAME | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | claimed |
| US-12522583-B2 | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KHORA SPV 1 LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| WO-2025129023-A1 | INDOLE AMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | RECTIFY PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | KHORA SPV 1, LLC (US) | 2025-06-17 | — | — | US | disclosed |
| CN-119424423-A | 4-Aminobut-2-enamide derivatives and salts thereof | 大鹏药品工业株式会社 | 2025-02-14 | — | — | CN | disclosed |
| EP-1191019-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZIMIDAZOLE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | Sankyo Company, Limited (JP) | 2002-03-27 | — | — | EP | disclosed |
| CN-1261529-A | Cationic monophenyl-nitro-diamino compounds and use in dyeing cutin fiber, dyeing composition containing said matter | OREAL (FR) | 2000-08-02 | — | — | CN | disclosed |
| EP-1018333-A2 | Use of cationic monobenzene nitroanilines for dyeing keratin fibres , compositions and dyeing process | L'OREAL (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-1018508-A1 | Cationic monobenzenic nitrophenylene diamines, their use for dyeing keratinic fibres, dye compositions containing them and dye processes | L'OREAL (FR) | 2000-07-12 | — | — | EP | disclosed |
| US-5587392-A | THERAPY FOR ESTROGEN DEPENDENT DISEASES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| EP-0684235-A1 | Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
| US-4432769-A | MADE BY REACTING 3-AMINO-4-NITRO-CHLOROBENZENE WITH GLYCEROL | L'OREAL (FR) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | MAPK1 1734/4885TSHR 652/4885MAPT 650/4885 |
| US-12331039-B2 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | MAPK1 521/4885TSHR 1346/4885MAPT 3513/4885 |
| US-20250333399-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | MAPK1 521/4885TSHR 1346/4885MAPT 3513/4885 |
| US-20090023929-A1 | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same | AZI2, CYC1, CCNI | MAPK1 2383/4885TSHR 3836/4885MAPT 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.